Clinical Trials Logo

Anterior Uveitis clinical trials

View clinical trials related to Anterior Uveitis.

Filter by:

NCT ID: NCT02879084 Completed - Anterior Uveitis Clinical Trials

Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis

Start date: August 2016
Phase:
Study type: Observational

This study investigates the variations in the retinal nerve fiber layer (RNFL) thickness during uncomplicated anterior and intermediate uveitis, respectively. The objectives are to 1 ) confirm the RNFL thickening during an uncomplicated anterior uveitis as described in the literature, 2) measure the RNFL thickness during an uncomplicated intermediate uveitis specifically and 3) describe the variation in time of RNFL thickness during the two types of uveitis.

NCT ID: NCT02765308 Completed - Anterior Uveitis Clinical Trials

Aqueous Humor Dynamics and Hypertensive Uveitis

Start date: August 2013
Phase: N/A
Study type: Observational

Uveitis is a disease that affects over 2 million people around the globe, and can ultimately lead to blindness. The proportion of patients with uveitis who become blind has not been reduced over the past 30 years, and this is therefore an area that demands further research. One of the major causes of blindness in uveitic patients is the development of uveitic glaucoma, which occurs in 10-20% of uveitic eyes. This is likely to occur for reasons related to the uveitis itself, but can also be caused as a side effect of the corticosteroids used to treat uveitis. The raised IOP in uveitis is more difficult to treat than other types of glaucoma. To enable more effective treatment of uveitic glaucoma, the investigators need to understand more clearly the mechanisms which underlie this process. The investigators therefore propose a study to examine the contribution of altered aqueous dynamics to the development of raised IOP in uveitis.

NCT ID: NCT02764697 Completed - Uveitis Clinical Trials

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

Start date: June 30, 2016
Phase: Phase 4
Study type: Interventional

Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. This inflammation, is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.

NCT ID: NCT02725177 Completed - Panuveitis Clinical Trials

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Start date: July 2016
Phase: N/A
Study type: Interventional

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

NCT ID: NCT02517619 Completed - Anterior Uveitis Clinical Trials

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

EGP-437-006
Start date: January 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

NCT ID: NCT01647529 Completed - Anterior Uveitis Clinical Trials

Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis

Virgan
Start date: July 2012
Phase: N/A
Study type: Interventional

Objective of this study is to investigate the intracameral level of ganciclovir following topical application of 0.15% ganciclovir gel (VIRGAN©) for Cytomegalovirus (CMV) anterior uveitis and endothelitis. Thirty patients who are diagnosed with CMV anterior segment infection, either uveitis or endothelitis, who have a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for CMV and have not had any form of ganciclovir treatment in the past 1 month, will be recruited in the study after taking an informed consent. with active CMV anterior segment infection confirmed by a positive aqueous real time PCR (RT-PCR) and have not had any form of ganciclovir treatment in the past 1 month were recruited in the study. Patients were given 0.15% ganciclovir gel 1cc 5 times a day for 6 weeks. Following 6 weeks of treatment, tears and aqueous samples will be collected. Aqueous will be sent for RT-PCR for CMV status. Ganciclovir drug level in both tears and aqueous will be measured by HPLC method. Clinically, degree of the intraocular inflammation, Intraocular pressure (IOP) and central corneal thickness (CCT) will be recorded at baseline and post-treatment.

NCT ID: NCT01505088 Completed - Anterior Uveitis Clinical Trials

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Start date: December 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

NCT ID: NCT01486693 Recruiting - Anterior Uveitis Clinical Trials

Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis

Start date: October 2011
Phase: N/A
Study type: Observational

The purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in Cytomegalovirus (CMV) anterior uveitis.

NCT ID: NCT01376362 Completed - Uveitis Clinical Trials

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

JakStat2
Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to investigate the safety and efficacy of ocular instillations of interferon gamma-1b as a potential treatment for cystoid macular edema (CME) secondary to uveitis.

NCT ID: NCT01156285 Recruiting - Anterior Uveitis Clinical Trials

Acute Anterior Uveitis: Psychic Burden and Pain

Start date: May 2010
Phase: N/A
Study type: Observational

Acute anterior uveitis (AU) is a common reason for attendance at ophthalmic outpatient clinics. The painfulness and the fear of a transient or even persistent loss of vision may markedly reduce the individual's subjective well-being and pose a psychological burden. This study will test the hypothesis that during an attack of AU the patient experiences a marked reduction in psychological and physical well-being. Prospective, hospital-based epidemiologic study using a patient questionnaire with standardized psychological tests and a pain scale.